BioCryst Pharmaceuticals Inc

BCRX remains in Stage 3 distribution with price below the declining 9/21 EMAs and 50 SMA, confirmed by the Bearish Pivot Point and failed rebound attempts. The medium-term bias is bearish, and short-term conditions favor immediate selling on any bounce into EMA resistance. The speculative strategy supports engaging in clear downtrend extensions.

• ↑Q1 2026 Orladeo net sales hit $148.3M, up 21% YoY
• ↑84% paid patient rate accelerates revenue conversion
• ↓Negative profitability metrics and earnings yield signal weak returns